![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Heron Therapeutics’ Zynrelef for Postoperative Pain
FDA Approves Heron Therapeutics’ Zynrelef for Postoperative Pain
![Heron Therapeutics Logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/HeronTherapeutics_Logo.gif?t=1576446934&width=430)
Heron Therapeutics’ Zynrelef (bupivacaine and meloxicam) has secured FDA approval as a postsurgical analgesic for up to 72 hours following knee replacements, abdominal hernia repairs and bunion removals.
The extended-release painkiller delivers the local anesthetic bupivacaine combined with a low dose of meloxicam, a nonsteroidal anti-inflammatory. In a phase 3 trial, the combination therapy resulted in less pain and fewer patients needing opioids postsurgery vs. bupivacaine alone, the current standard of care.
The San Diego, Calif.-based drugmaker plans to launch Zynrelef in July.
Upcoming Events
-
21Oct